论文部分内容阅读
目的:探讨血清胸苷激酶1(thymidine kinase1,TK1)检测对乳腺癌辅助诊断及术后化疗效果评估的意义。方法:应用免疫印迹—增强化学发光法(ECL)检测48例乳腺肿瘤患者的血清TK1水平,并对其中随访1～3个月的14例术后化疗的血清TK1水平进行检测。结果:10例完成4～6个周期化疗后的血清TK1降低并接近正常人水平,4例血清TK1未降反升。随访1年后,有1例发生骨转移。结论:血清TK1水平反映细胞增殖,与病灶大小有一定相关性,连续跟踪结果有利于对乳腺癌治疗效果的辅助诊断,对临床监视肿瘤疗效具有临床意义。
Objective: To investigate the value of serum thymidine kinase 1 (TK1) in the diagnosis of breast cancer and the evaluation of postoperative chemotherapy. Methods: The levels of serum TK1 in 48 patients with breast cancer were detected by Western blotting and enhanced chemiluminescence (ECL). The level of serum TK1 was measured in 14 patients who were followed up for 1 to 3 months. Results: The serum TK1 in 10 patients after 4 to 6 cycles of chemotherapy was lower than that in normal people, and the serum TK1 in 4 patients did not go up and down. One year after follow-up, bone metastasis occurred. CONCLUSION: The level of serum TK1 reflects the cell proliferation and has some correlation with the size of the lesion. The continuous follow-up results are helpful for the auxiliary diagnosis of the therapeutic effect of breast cancer and have clinical significance for clinical monitoring of tumor efficacy.